Skip to main content
. 2018 Jan 23;2:PO.17.00160. doi: 10.1200/PO.17.00160

Fig A3.

Fig A3.

Plasma ALK (anaplastic lymphoma kinase) fusion and ALK mutation allelic fractions of MGH919 (left) and MGH947 (right) during treatment with ALK inhibitors. The y-axis indicates the allelic fraction of the ALK fusion and ALK mutations. Chemo, chemotherapy; Criz, crizotinib.